GlaxoSmithKline PLC GSK Chairman succession process (6088N)
January 21 2019 - 01:00AM
UK Regulatory
TIDMGSK
RNS Number : 6088N
GlaxoSmithKline PLC
21 January 2019
Issued: 21 January 2019, London UK - LSE Announcement
GSK announces succession plan to appoint new Chairman
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Sir
Philip Hampton has informed the Board of his intention to step down
as non-executive Chairman and the Board has started the process to
find a successor.
Sir Philip was appointed to the Board on 1(st) January 2015. He
was appointed as Deputy Chairman from 1(st) April 2015 and as
Chairman from 7(th) May 2015.
Sir Philip said: "It is a privilege to serve as Chairman of GSK.
It is one of the UK's great companies and under Emma Walmsley's
leadership, GSK has made very good progress with a new strategy and
new approach to R&D. Following the announcement of our deal
with Pfizer and the intended separation of the new consumer
business, I believe this is the right moment to step down and allow
a new Chair to oversee this process through to its conclusion over
the next few years and to lead the Board into this next phase for
GSK."
Vindi Banga, GSK's Senior Independent Director, said: "The Group
has a clear strategy, is delivering improved operating performance
and has a clear pathway forward, this is a good time to start the
process to find Philip's successor."
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com.
GSK enquiries:
UK Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Tim Foley +44 (0) 20 8047 (London)
5502
Analyst/Investor Sarah Elton-Farr +44 (0) 208 047 (London)
enquiries: 5194
Danielle Smith +44 (0) 20 8047 (London)
7562
James Dodwell +44 (0) 20 8047 (London)
2406
Mel Foster-Hawes +44 (0) 20 8047 (London)
0674
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Cautionary statements regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item
3.D Principal risks and uncertainties in the company's Annual
Report on Form 20-F for 2017.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBBMFTMBATMRL
(END) Dow Jones Newswires
January 21, 2019 02:00 ET (07:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024